TABLE 1.
Demographic and clinical characteristics of patients treated with sorafenib
|
Sorafenib dose/day
|
P | ||
|---|---|---|---|
| 800 mg (n=33) | 400 mg (n=66) | ||
| Age, years, mean ± SD | 58.6±10.4 | 63.4 ±11.1 | 0.1 |
| Sex | |||
| Male/female | 94/6 | 73/27 | 0.02 |
| Ethnicity | |||
| Asian | 45 | 60 | 0.2 |
| Caucasian | 55 | 40 | 0.2 |
| Etiology | |||
| Hepatitis B virus | 45 | 44 | 1.0 |
| Hepatitis C virus | 18 | 30 | 0.23 |
| Alcohol | 21 | 6 | 0.04 |
| Eastern Cooperative Oncology Group | |||
| 0 | 51 | 42 | 0.4 |
| 1 | 30 | 33 | 0.8 |
| 2 | 12 | 15 | 0.8 |
| 3 | 7 | 10 | 0.7 |
| Child-Pugh score | |||
| A | 90 | 90 | 1.0 |
| B7 | 4 | 7 | 0.7 |
| B8–9 | 6 | 3 | 0.6 |
| Barcelona Clinic Liver Cancer staging, % | |||
| B | 42 | 45 | 0.83 |
| C | 58 | 55 | 0.83 |
| AFP ng/mL, median (range) | 140 (1.5–200,000) | 158 (2–400,000) | |
| Previous treatments | |||
| TACE | 55 | 55 | 1.00 |
| Resection | 27 | 21 | 0.61 |
| Ablation* | 6 | 14 | 0.33 |
| Combination | 21 | 23 | 1.00 |
| Tumour characteristics | |||
| Multinodular | 60 | 42 | 0.09 |
| Extrahepatic spread | 30 | 30 | 1.00 |
| Portal vein thrombosis | 15 | 38 | 0.02 |
Data presented as % unless otherwise indicated. Bolded values indicate statistical significance.
*
Including radiofrequency ablation and lipiodol ablation. AFP Alpha-fetoprotein; TACE Transarterial chemoembolization